News
Teos expects to absorb nearly $25 million in one-time costs for severance and termination payments. The biotech had 173 ...
Teos will look to distribute its cash reserves to shareholders, along with proceeds raised from selling pipeline assets.
23h
Stocktwits on MSNiTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’Shares of biopharmaceutical company iTeos Therapeutics, Inc. (ITOS) traded 20% higher on Wednesday morning after the company ...
By Kamal Choudhury (Reuters) -ITeos Therapeutics plans to wind down its operations and sell its assets, including experimental cancer treatments and an obesity drug, the company said on Wednesday, two ...
Shares in iTeos Therapeutics surged after the company said it would wind down operations. The stock was up 27% at $10.87 in premarket trading. Shares were already up 11% year-to-date when the market ...
ITeos Therapeutics is throwing in the towel. | iTeos Therapeutics is throwing in the towel. Two weeks after axing its ...
Teos Therapeutics (ITOS) stock surges 25% as the company announces plans to wind down operations, focusing on shareholder ...
Pharmaceutical share prices fell last Monday, after US President Donald Trump vowed to reduce drug prices in the USA by as ...
Almost a third of Americans are more than a year behind in cancer screening, more than half of them because of out-of-pocket ...
As of Thursday, May 15, iTeos Therapeutics, Inc.’s ITOS share price has surged by 5.79%, which has investors questioning if ...
Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all development and ongoing trials.
Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results